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Lowering blood pressure in 2003
Abstract

The foundation of treatment for patients with hypertension is ongoing use of lifestyle measures such as
physical exercise, weight reduction, and salt restriction. There should be emphasis on reduction of total
cardiovascular risk, including smoking cessation and achievement of goal blood pressures. There are now five
classes of first-line blood-pressure-lowering drugs - diuretics, β-blockers, angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers and calcium antagonists. In most patients, the choice of drug will be
guided by the clinical situation in the individual patient, including the presence of target organ damage,
diabetes, established vascular or kidney disease, or other comorbidities. In the absence of such clinical
indications, start drug therapy with a low-dose diuretic. Combination therapy will be needed in around twothirds of patients, and a diuretic will normally form one element of most combinations, with the second or
third drug coming from among the remaining four. Consider the use of fixed-dose combinations to improve
adherence to therapy. Use long-acting, once-daily preparations.
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Lowering blood pressure in 2003
John P Chalmers and Leonard F Arnolda
T HE RECOMMENDATIONS of the recent international
guidelines on hypertension, the 1997 Sixth Report of the
Joint National Committee (JNC VI)1 and the 1999 World
Health Organization–International Society of Hypertension
Guidelines (WHO-ISH 1999),2 had many principles in
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stratify patients according to the severity of risk to determine
prognosis and treatment.1,2 However, these major guidelines
differed in their recommendations for beginning drug treatment.
JNC VI recommended that, in the absence of compelling
indications such as previous myocardial infarction or diabetic nephropathy, drug treatment should begin with diuretics or ␤-blockers. This was because, at that time, there was
only limited evidence that the newer agents — such as
angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers
(CCBs) or ␣-blockers — reduced morbidity or mortality in
patients with hypertension.1
In contrast, the WHO-ISH 1999 guidelines recommended that any of these major classes of drugs could be
used to initiate drug treatment, according to the clinical
situation in the individual patient. This recommendation
reflected the premise that the benefits of antihypertensive
drugs were mainly dependent on their blood-pressurelowering efficacy rather than on effects specific to particular
drug classes.2
Most experts in the field agreed that these differences in
recommendations arose from lack of evidence, and that
randomised trials of the newer drugs were necessary to
resolve the uncertainty.1,2 Since the late 1990s, many clinical trials examining these issues have been completed, so
that, by the turn of the century, there was sufficient evidence
to establish that ACE inhibitors and CCBs do reduce the
risks of coronary heart disease and stroke in patients with
hypertension when compared with placebo.3
In the past year, the results of two of the most awaited
trials have become available. These are:
■ The Antihypertensive and Lipid Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT), the largest comparInstitute for International Health, University of Sydney,
Sydney, NSW.
John P Chalmers, MD, FRACP, Professor of Medicine.

West Australian Institute for Medical Research, School of
Medicine and Pharmacology, University of Western Australia,
Perth, WA.
Leonard F Arnolda, PhD, FRACP, Professor of Cardiology.
Reprints will not be available from the authors. Correspondence: Professor
John P Chalmers, Institute for International Health, University of Sydney,
Newtown, NSW 2042. chalmers@iih.usyd.edu.au

306

ABSTRACT
■

The foundation of treatment for patients with hypertension is
ongoing use of lifestyle measures such as physical exercise,
weight reduction, and salt restriction.

■

There should be emphasis on reduction of total
cardiovascular risk, including smoking cessation and
achievement of goal blood pressures.

■

There are now five classes of first-line blood-pressurelowering drugs — diuretics, ␤-blockers, angiotensinconverting enzyme inhibitors, angiotensin receptor blockers
and calcium antagonists.

■

In most patients, the choice of drug will be guided by the
clinical situation in the individual patient, including the
presence of target organ damage, diabetes, established
vascular or kidney disease, or other comorbidities.

■

In the absence of such clinical indications, start drug therapy
with a low-dose diuretic.

■

Combination therapy will be needed in around two-thirds
of patients, and a diuretic will normally form one element
of most combinations, with the second or third drug coming
from among the remaining four.

■

Consider the use of fixed-dose combinations to improve
adherence to therapy.

■

Use long-acting, once-daily preparations.
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ative study of blood-pressure-lowering drugs ever completed,4 and
■ The Second Australian National Blood Pressure Study
(ANBP2), a smaller head-to-head comparison of diuretics
and ACE inhibitors, carried out entirely within general
practice in Australia.5
Here, we review, primarily, the results of ALLHAT and
ANBP2 in the context of the accumulated evidence about
the newer classes of blood-pressure-lowering drugs reported
since JNC VI and WHO-ISH 1999 were published.1,2 Our
review is made more timely by the release of JNC VII in
May this year,6 with recommendations based predominantly
on the outcomes of ALLHAT4 and the recent European
Guidelines, released in June 2003 by the European Society
for Hypertension jointly with the European Society of
Cardiology.7
The importance of the effective treatment of hypertension
has been reinforced in a most powerful way by the recent
World Health Organization report (WHO Report 2002),8 as
highlighted in two shorter articles in the Lancet.9,10 These
reports confirm that, in developed countries, blood pressure
is the single most important contributor to global mortality
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from disease. A systolic blood pressure greater than
115 mmHg is estimated to be responsible for two thirds of
all deaths from stroke and for half of deaths from ischaemic
heart disease at the global level.8-10 The reports estimate
that intervention directed at lowering blood pressure and
reducing cholesterol levels could halve the burden of cardiovascular disease.8-10
Trials outcomes before December 2002
The Blood Pressure Lowering Treatment Trialists’
Collaboration, 2000

The major trials of newer antihypertensive agents reported
before the end of 2000 were systematically reviewed by the
Blood Pressure Trialists’ Collaboration, which consists of
the principal investigators of around 36 major randomised
trials of blood-pressure-lowering treatment in patients with
hypertension or related cardiovascular diseases.3 It is coordinated by Stephen MacMahon and Bruce Neal from the
Institute for International Health in Sydney. The second
round of analyses, including the data from ALLHAT and
ANBP2, has been submitted to the Lancet and should be
published before the end of this year.3 Meta-analysis of the
data confirmed that ACE inhibitors and CCBs were safe
and effective for preventing major cardiovascular events (a
composite endpoint comprising myocardial infarction,
stroke, heart failure and cardiovascular death) as well as
stroke and cardiovascular death taken separately. In addition, ACE inhibitors were shown to prevent coronary heart
disease and reduce total mortality.3
Comparisons were made between the “newer drugs”
(ACE inhibitors, CCBs) and older drugs (diuretics and ␤blockers lumped as “conventional therapy”, without seeking
to distinguish between them). The efficacy of ACE inhibitors was not different from diuretics/␤-blockers for any
outcome, whereas the analysis suggested that CCBs might
be more effective than diuretics/␤-blockers in preventing
stroke, but marginally less effective in preventing coronary
events or heart failure.3 Direct comparisons between CCBs
and ACE inhibitors suggested that the latter were more
effective in preventing coronary disease or heart failure.
In summary: Overall, the net effect on cardiovascular
morbidity and mortality of ACE inhibitors, CCBs and
diuretics/␤-blockers appears to be similar, although total
numbers were small and confidence intervals were wide, so
that clinically meaningful differences between treatments
could not be excluded for some cause-specific effects on
particular outcomes.
HOPE and PROGRESS trials

Both the HOPE11 and PROGRESS12 trials randomly allocated individuals to treatment arms on the basis of vascular
disease rather than hypertension, to try to reduce morbidity
and mortality in high-risk patients with a broad range of
blood pressures.
In the PROGRESS trial, people with previous stroke or
transient ischaemic attack were allocated to placebo or to
MJA
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active treatment with perindopril and discretionary use of
the diuretic indapamide. Clear benefits of treatment
included a 28% reduction in stroke (4% absolute reduction
over four years) and a 26% reduction in major vascular
events (a composite endpoint comprising stroke, myocardial
infarction and cardiovascular death). Greater reductions, of
the order of 40%, were observed with the larger blood
pressure reductions obtained when patients routinely
received the combination of perindopril and indapamide.
In the HOPE study, patients with established vascular
disease (especially coronary heart disease), or with diabetes
with or without vascular disease, were randomised to treatment with ramipril or placebo. Each component of the
composite endpoint of stroke, myocardial infarction or
cardiovascular death was reduced by treatment with ramipril. A modest difference in systolic blood pressure (3–
4 mmHg) was observed throughout the trial.
In summary: These two studies confirm that, in patients
with pre-existing coronary disease, cerebrovascular disease
or diabetes, lowering blood pressure reduces the risk of
cardiovascular morbidity and mortality in both patients with
hypertension and those with normal blood pressure.11,12
Studies with angiotensin receptor blockers

The LIFE study provided the first evidence of the effects of
ARBs on cardiovascular events in patients with hypertension
and evidence of target organ damage, manifest as leftventricular hypertrophy on electrocardiography.13 This study
compared initial therapy with the ␤-blocker, atenolol, and the
ARB, losartan. The risk of the primary endpoint (death,
myocardial infarction or stroke) was 2.8% in the atenolol
group and 2.4% in the losartan group — 13% higher in
patients treated with atenolol, mainly because of a significant
25% excess of strokes in this group, even though the reduction in blood pressure was similar in the two groups.13
While the authors of LIFE propose that the results
establish that losartan confers specific benefits beyond
lowering of blood pressure, it is equally possible that ␤blockers (and atenolol in particular) are less effective in
preventing strokes than thiazides. Indeed, the reductions in
stroke in the Medical Research Council mild hypertension
trial14 and in stroke and heart attack in the Medical
Research Council trial in older adults15 were very much
smaller (or absent) in the ␤-blocker arm of these studies
than in the thiazide diuretic arm.14,16
The SCOPE trial was unable to demonstrate clear benefit of
treatment with an ARB in elderly patients with hypertension,
partly because of extensive use of antihypertensive therapy in
the placebo group, 84% of whom received blood-pressurelowering drugs.17 The only other studies of ARBs in hypertension that report outcome data are three studies in patients with
type 2 diabetes and hypertension.18-20 These studies focused
on how treatment affected the progression of renal disease.
They provided evidence that ARBs slowed the progression of
diabetic nephropathy, but were not designed to detect differences in cardiovascular outcomes, and were too small to
confirm an effect on stroke, myocardial infarction or major
cardiovascular events either individually or in aggregate.
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In summary: ARBs are effective in lowering blood pressure and are well tolerated. They appear to be more effective
than ␤-blockers in preventing adverse cardiovascular outcomes, especially stroke, in patients with hypertension, but
evidence on the relative benefits of this group of drugs is still
limited.
Review of the ALLHAT and ANBP2 trials
ALLHAT

ALLHAT was a randomised, double-blind trial designed to
determine whether the incidence of the primary outcome,
fatal coronary heart disease or non-fatal myocardial infarction, differed between treatments initiated with a diuretic
(chlorthalidone) versus treatment initiated with a CCB
(amlodipine), an ACE inhibitor (lisinopril) or an ␣-blocker
(doxazosin).4 Secondary outcomes included a composite
endpoint (combined cardiovascular disease) as well as the
separate elements of that endpoint (stroke, coronary heart
disease, heart failure and cardiovascular death). More than
42 000 participants with hypertension, aged 55 years or
older, were randomly allocated to the four treatment arms
between 1994 and 1998. The doxazosin arm, involving
some 9000 patients, was discontinued in January 2000
because of an excess of combined cardiovascular disease,
heart failure and stroke.21 The results of the remaining three
arms of ALLHAT were reported at the end of 2002.4
The most striking feature of ALLHAT was the absence of
any difference in the frequency of the primary outcome
(fatal coronary heart disease or non-fatal myocardial infarction) or in all-cause mortality between any of the treatment
groups, including the doxazosin group.4,21 Another outstanding feature was the success of treatment with low-dose
diuretic. Across a large number of comparisons of the
diuretic versus the ACE inhibitor, the CCB and the ␣blocker, the diuretic was either equally effective in the
primary outcome, or superior in some secondary outcomes.4,21
The CCB, amlodipine, stood up very well in the comparison with the diuretic, with almost identical reductions in
blood pressure, and almost indistinguishable effects in most
outcomes. The exception was for prevention of heart failure,
where the CCB was clearly inferior by around a third.4
However, there was no suggestion whatever that the CCB
increased mortality or morbidity due to cancer, severe
bleeding, or coronary disease, as had been suggested by
Furberg and colleagues, largely on the basis of observational
studies.15,22 This emphasises the importance of evidence
from large, well conducted, randomised trials.
With the ␣-blocker, doxazosin, the reduction in systolic
pressure was 2–3 mmHg less than that seen with the diuretic, and at the time that treatment arm was terminated, the
risk of heart failure, combined cardiovascular disease and
stroke were increased by 104%, 25% and 19%, respectively.21 In the absence of any other major completed or
ongoing trials with ␣-blockers, it seems reasonable to relegate this class of drugs to second line status, for use as
adjunct therapy.
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With the ACE inhibitor, lisinopril, the reduction in
systolic blood pressure was also 2 mmHg less than that
obtained with the diuretic, and the risks of combined
cardiovascular disease, stroke and heart failure were
increased by 10%, 15% and 19% respectively. However,
there were some factors in the trial design that favoured the
diuretic. The first was the larger fall in systolic blood
pressure, which will have accounted for some of the greater
benefits obtained with the diuretic. The second was the
large proportion of African American patients (35%), as it is
accepted that ACE inhibitors are less effective than diuretics
in lowering blood pressure in African American people.1,6
The third was the restriction in choice for additional bloodpressure-lowering drugs, so that the second choice, a ␤blocker in most instances, was much less appropriate for
combination with an ACE inhibitor than with a diuretic.1,2,6,7 Finally, the criteria for heart failure were “soft”,
and when a “harder” heart failure endpoint was chosen
(heart failure causing death or hospitalisation), the difference was no longer significant.4
In summary: ALLHAT establishes the prime importance
of blood-pressure lowering for reducing the risk of cardiovascular morbidity and death in patients with hypertension,
and shows there is little difference between the benefits
conferred by diuretics, ACE inhibitors and CCBs, all of
which are safe and effective. ␣-Blockers are less effective and
should be kept as second-line drugs. CCBs are less effective
for preventing heart failure, and not indicated for this
purpose. Diuretics may have advantages in preventing
stroke, though this advantage applies only in African American people.
ANBP2

ANBP2 was an open-labelled randomised study
with blinded endpoints. 5 Over 6000 patients
attending
some
2000
general
practices
in
Australia were randomly allocated to treatment, commencing with an ACE inhibitor (preferably but not exclusively
enalapril) or a diuretic (preferably but not exclusively hydrochlorothiazide). After 4 years of follow-up, ANBP2 reported
an 11% reduction in the primary endpoint (all-cause mortality and all cardiovascular events), which was only of
borderline statistical significance (P = 0.05). The average
age of patients in ANBP2 was 72 years and there were no
African American patients in this trial. While there was a
17% reduction in this primary endpoint in men, there was
no benefit in women.
The sample size of ANBP2 gave it limited power to detect
small differences of the order of 10%–12% and to determine
changes in subgroups and in secondary endpoints, such as
cardiovascular death, and fatal or non-fatal stroke or myocardial infarction. The pre-specified primary endpoint (cardiovascular mortality and cardiovascular events) 23 was
changed in the main study report.5 However, some of the
strengths of ANBP2 were that the reductions in blood
pressure were much closer, and flexibility in choice of
MJA
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additional blood-pressure-lowering drugs made the comparison between ACE inhibitor and diuretic fairer in many ways
than that in ALLHAT.
Comparison of ANBP2 and ALLHAT

While the primary and secondary endpoints were different
in the two studies, it is notable that the comparison for the
primary outcome revealed no significant difference between
ACE inhibitor and diuretic in ALLHAT, and only a marginally significant 11% difference in favour of the ACE inhibitor in ANBP2.
The biggest difference between the trials was in the
populations being studied. In ALLHAT, participants were
younger (mean age 67 years versus 72 years in ANBP2), and
35% were African Americans, whereas there were no African American participants in ANBP2. The importance of
the African American cohort in ALLHAT is evident in the
results for stroke. While the results for stroke risk may
appear different — no significant difference in ANBP2 and
15% advantage to the diuretic in ALLHAT — there was no
difference in stroke risk in the non-African American participants in ALLHAT. Thus, the appropriate conclusion for an
Australian population, taking the two studies together, is
that the benefits of both classes of drug in reducing the risk
of stroke are much the same. Similarly, when the risk of a
first coronary event (fatal or non-fatal) is examined, being
the primary outcome for ALLHAT and a secondary outcome for ANBP2, it is evident that there is no significant
difference between diuretics and ACE inhibitors in either
study.
In summary: The main conclusions from these two
studies are that differences between the benefits of different
drug classes are very slight and restricted to cause-specific
effects on particular outcomes, and that the key is effective
reduction in blood pressure.
Interpretation of the evidence — old and new

When all the evidence is reviewed, including that leading up
to JNC VI and WHO-ISH 1999,1,2 more recent trials, and
finally ALLHAT and ANBP2,4,5 the messages that emerge
are that:
■ There are now five first-line groups of blood-pressurelowering drugs that are both safe and effective for treating
patients with hypertension and those with established vascular disease, including coronary heart disease, cerebrovascular disease, diabetes and progressive renal disease. These
five drug groups are diuretics, ␤-blockers, ACE inhibitors,
ARBs and CCBs.
■ The major benefit derived from using these five groups of
drugs stems from their common actions in lowering blood
pressure rather than from particular class-specific effects on
other aspects of cardiovascular function. Thus, the ALLHAT trial was not able to differentiate between diuretics,
ACE inhibitors, CCBs and even ␣-blockers in their effects
on a primary composite endpoint of fatal and non-fatal
myocardial infarction, nor in their effects on all-cause
mortality.4 In the same way, the meta-analysis in 2000 by
MJA
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the Blood Pressure Lowering Treatment Trialists’ Collaboration could not differentiate between the effects of “conventional treatment” with diuretics and/or ␤-blockers and
ACE inhibitors or CCBs, on “major cardiovascular events”
(a composite endpoint combining stroke, myocardial infarction, heart failure and vascular death).3 The next analysis
from this collaboration, due to be published this year, will
have much greater power to differentiate between drug
classes, but perusal of the evidence suggests that it will
confirm this broad equivalence in reducing overall cardiovascular risk.
■ The only differences between the effects of the different
drugs reside, or potentially reside, in cause-specific effects
on outcomes such as myocardial infarction, stroke, and
heart failure. Even here, it is clear that most differences that
may emerge, if any do, will be moderate and of the order of
around no more than 8%–12%. The one exception is for
prevention of heart failure, where the evidence is very clear
— calcium antagonists confer no benefit and may have a
deleterious effect, and diuretics and ACE inhibitors are
clearly superior by a margin of between a quarter and a
third. The same holds true for ␣-blockers, for which the
only major comparative study (ALLHAT4) terminated the
doxazosin comparison with chlorthalidone early because of
a doubling in the rate of heart failure compared with
diuretics.21
When all the available evidence is pooled in the next
analysis from the Blood Pressure Lowering Treatment Trialists’ Collaboration, some drug groups may be shown to
prevent stroke more effectively than others. It seems possible

1: Principles of management
Thresholds for initiation of drug therapy
Low-risk patients with hypertension (minimal elevation of blood
pressure; no other risk factors)
■ Begin with lifestyle measures
■ Start drug therapy if blood pressure is still over 140/90 mmHg
after 6 months
Medium-risk patients with hypertension (moderate or minimal
elevation of blood pressure; other risk factors and conditions
present)
■ Start drug therapy if blood pressure is over 140/90 mmHg
Patients with diabetes, chronic kidney disease, or established
vascular disease
■ Start drug therapy if blood pressure is in the “pre-hypertensive
range” (120–139 mmHg systolic; 80–89 mmHg diastolic)
Goals of therapy
■ To address all risk factors and conditions, so as to minimise total

cardiovascular risk.
All patients with hypertension
■ Reduce blood pressure below 140/90 mmHg
High-risk patients with or without elevated blood pressure
■ Aim at blood pressure below 130/80 mmHg in patients with

diabetes, chronic kidney disease or established vascular
disease.
Tables for stratifying patients according to absolute cardiovascular risk and
levels of blood pressure are available.1,2,6,7
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that CCBs may be slightly superior to ACE inhibitors and
even to diuretics, though such margins, even if significant,
are likely to be of the order of no more than 10%. It also
seems clear that diuretics are superior to ␣-blockers in
preventing stroke by close to 20%,21 and possibly to ACE
inhibitors by a more modest margin of 5%–10%, although
this latter result may be more relevant to African Americans
than white people.4 It seems likely that ␤-blockers are less
effective than ARBs in preventing stroke, though this is
based on a single study (LIFE13) and awaits confirmation.
Another group of studies has highlighted the importance
of lowering blood pressure in patients at high risk of adverse
cardiovascular events, such as those with established vascular disease or diabetes, whether or not they have hypertension. Thus, it is clear from the HOPE study11 and the
PROGRESS trial12 that patients with coronary heart disease
or cerebrovascular disease derive substantial benefits from
treatment with blood-pressure-lowering drugs regardless of
whether they have hypertension. A similar pattern is seen in
patients with diabetes, in whom treatment with ARBs has
reduced the progression of renal disease,18-20 independent of
baseline blood pressure. These results are consistent with
the results of major epidemiological studies that have confirmed the continuous nature of the relationships between
blood pressure and cardiovascular risk right down into the
normotensive range.24-26
The evidence on use of blood-pressure-lowering drugs in
patients with diabetes, kidney disease or established vascular
disease who do not have hypertension is still quite limited,
and mainly dependent on randomised studies against placebo. There are few comparative studies in such patients
that assess the relative value of different classes of bloodpressure-lowering drugs. It is possible that these are the
groups of patients in whom particular groups of drugs may
have class-specific actions that are advantageous.

major risk factors for cardiovascular disease. These include
raised cholesterol levels, obesity and smoking, target organ
damage, and associated disorders such as diabetes, renal,
coronary and cerebrovascular disease. The use of bloodpressure-lowering drugs should be considered in all patients
with diabetes, renal disease or established vascular disease,
whether they have hypertension or not. Comprehensive
tables are provided in the most recent guidelines, for
stratifying patients according to absolute cardiovascular risk
and levels of blood pressure.1,2,6,7
Lifestyle measures

Instituting lifestyle measures to reduce cardiovascular risk
and to lower blood pressure should continue to be the
foundation for managing all patients with hypertension,
diabetes or established vascular disease. This should include
smoking cessation, weight reduction, salt restriction and
increasing physical exercise wherever applicable. In some
patients with a low risk of adverse cardiovascular events or
slight elevation of blood pressure, lifestyle measures alone
may achieve the goals of therapy without recourse to
treatment with blood-pressure-lowering drugs.
Goals for blood-pressure-lowering therapy

The key to reducing the risk of blood-pressure-related
disease is lowering the blood pressure. Therefore, the active
implementation of a management plan to achieve a goal
blood pressure is the most important part of management,
and far more important than the choice of drugs (Box 1).
The primary focus should be on reaching the goal for
systolic blood pressure, which is generally harder to achieve,
but more closely linked to reduction in cardiovascular risk.
Indications for initiating blood-pressure-lowering drug therapy

Recommendations for lowering blood pressure
in 2003
Risk stratification and the importance of reducing the total
cardiovascular risk

It is essential to assess each patient’s risk profile to stratify
the cardiovascular risk and identify and manage the other

There is widespread agreement that drugs to lower blood
pressure should be used in patients with blood pressure
readings persistently higher than 140/90 mmHg, even in
low-risk individuals without other risk factors (Box 1). Even
more important is the widespread recognition and recommendation that, in high-risk individuals, blood-pressurelowering therapy should be initiated at pressures in a range

2: Individualisation of therapy
Disorder
Isolated systolic hypertension

Diuretics ␤-Blockers
✓
✓

Stable angina

✓

Heart failure

✓

Cerebrovascular disease

✓

Diabetes

✓

Aldosterone
antagonists

✓

After myocardial infarction

Chronic kidney disease (especially diabetes)

Angiotensin-converting
Angiotensin
Calcium
enzyme inhibitors
receptor blockers antagonists

✓

✓

✓
✓

✓

✓

✓

✓
✓

✓

✓

✓

✓

✓

Ticks indicate the various classes of drugs that are particularly indicated for the conditions shown. In each case one or more of the classes ticked may be used
according to the clinical situation.
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3: Effective blood-pressure-lowering drug
combinations2,7,27
■ Diuretics and ␤-blockers
■ Diuretics and angiotensin-converting enzyme inhibitors

or angiotensin receptor blockers

the most recent meta-analysis conducted by the Blood
Pressure Lowering Treatment Trialists’ Collaboration,3 it is
clear that diuretics are as effective as any other class of drugs
for preventing combined vascular endpoints, and for most
cause-specific endpoints such as stroke, heart attack and
heart failure.4,6

■ Diuretics and calcium antagonists
■ Calcium antagonists and ␤-blockers
■ Calcium antagonists and angiotensin-converting enzyme

inhibitors or angiotensin receptor blockers

4: “Take-home messages” for clinicians
■ Assess and treat all other risk factors and disorders in each

■

■

■
■

patient so as to reduce total cardiovascular risk, not just blood
pressure.
Pursuing an active blood-pressure-lowering regimen until goal
blood pressures are achieved is more important than the choice
of drug.
The choice of drug will often be facilitated by clinical pointers in
the individual patient; in the absence of such pointers, start with a
low-dose diuretic.
Combination therapy will be needed in most patients and lowdose diuretics will normally form one element of such a regimen.
There are five first-line classes of blood-pressure-lowering drugs,
all of them safe and effective in reducing cardiovascular morbidity
and mortality — diuretics, ␤-blockers, angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers and calcium
antagonists.

that was previously considered within the “normal range”,
but that was termed “pre-hypertensive” in the recent JNC
VII report6 (Box 1).
Choice of drugs for initiating therapy
Individualisation of therapy in patients with clinical pointers
to particular drug classes

In most patients who need blood-pressure-lowering drugs,
the choice of agents to initiate therapy is determined by the
clinical profile of the patient. This includes illnesses that
mitigate against the choice of some drug classes (eg, asthma
and ␤-blockers), or comorbid conditions such as diabetes or
vascular disease that suggest drug classes with particular
advantage or compelling evidence of benefit (Box 2). This is
particularly true in ageing populations where multiple illnesses are increasingly coexistent.
Other aspects of the patient’s profile may also help
determine the choice — for example diuretics and CCBs are
clearly more effective in African American patients than are
ACE inhibitors or ␤-blockers.4,6
Choice of drugs in patients without clinical pointers
to particular drug classes

This choice, which often stirs the greatest controversy, has
probably been made easier by the results of ALLHAT and
by the totality of the evidence now available, which suggests
that, in the absence of particular reasons to the contrary,
46
drug therapy should start with a low-dose diuretic. , This is
4
because, from both the largest study (ALLHAT ) and from
MJA
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Combination therapy

Around two-thirds of patients will require combination
therapy with at least two drugs.1,2,6,7 Diuretics should
normally be one element of combination therapy, and where
diuretics have been used to initiate drug therapy, the second
drug will be chosen from among the other four groups of
first-line agents — ACE inhibitors, ARBs, ␤-blockers and
CCBs. Particularly effective combinations are shown in Box
3. In white or Asian patients, one of the most effective
combinations is a diuretic with an ACE inhibitor or an ARB;
in African American patients, the combination of a diuretic
and a CCB might be preferred. There are few data on which
to base recommendations tailored to Torres Strait Islanders
or Aboriginal Australians.
It is noteworthy that JNC VII,6 WHO-ISH 19992 and the
new European Guidelines,7 all recommend the use of fixed
dose combinations, particularly fixed low-dose combinations, and of long acting, once daily preparations to improve
adherence to therapy and diurnal control of blood pressure.
JNC VII and the European Guidelines further recommend
that fixed dose combinations may be used to initiate therapy.6,7 JNC VII suggests these be used to initiate therapy
when the gap between the patient’s blood pressure and goal
blood pressure is at least 20/10 mmHg.6
An overall approach to managing individual patients with
hypertension or with blood-pressure-related disease is proposed in the abstract of this article. “Take-home messages”
for the practising doctor are shown in Box 4.
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